April 22 (Reuters) - Drugmaker Bristol Myers Squibb
said it has signed a $380 million deal with contract
manufacturer Cellares to manufacture its CAR-T cell therapies in
the United States, EU and Japan.
The collaboration will help Bristol Myers to expand its
manufacturing capacity due to increasing demand. The company
said in February it was looking to launch both its CAR-T blood
cancer therapies Abecma and Breyanzi in a number of new
countries this year.
CAR-T therapy involves removing a patients' own T cells - a
key component of the immune system - engineering them to
recognize and attack malignant cells, and re-infusing them.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)